Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibody drugs

This page shows the latest monoclonal antibody drugs news and features for those working in and with pharma, biotech and healthcare.

Roche builds on Immunocore ImmTAC deal

Roche builds on Immunocore ImmTAC deal

According to the company, the molecules can access up to nine-fold more target antigens than typical antibody-based approaches, including industry-leading monoclonal antibody-based drugs, which can only recognise ... If the candidate makes it through to

Latest news

  • Novartis plans major expansion of French antibody facility Novartis plans major expansion of French antibody facility

    Novartis has set aside $100m to expand a production facility for monoclonal antibody (Mab) drugs in France, planning to boost capacity by 70%. ... inflammatory and anti-rejection drugs, as well as antibodies in late-stage clinical development.

  • J&J starts to feel biosimilar competition bite J&J starts to feel biosimilar competition bite

    We also have a [US] patent for the Remicade antibody that doesn't expire until September 2018 that you can be sure we will continue to vigorously defend," he told investors ... towards the end of 2013 that the first monoclonal antibody (mAb) drugs

  • EMA seeks comment on final biosimilar guidance EMA seeks comment on final biosimilar guidance

    cost versions of pricey branded medicines that account for a major chunk of the drugs budget in increasingly cash-strapped national healthcare systems. ... Growth will accelerate in the ensuing years, it says, as more and more copies of early-generation

  • Takeda files IBD drug vedolizumab in Europe Takeda files IBD drug vedolizumab in Europe

    Vedolizumab is a gut-selective monoclonal antibody that targets the alpha4beta7 integrin on leukocytes thought to be involved in the development of ulcerative colitis (UC) and Crohn's disease (CD), and ... UC - will outpace a decline in sales of older

  • Biomarkers predict rheumatoid drug success

    had previously experienced an inadequate response to other disease-modifying anti-rheumatic drugs (DMARDs) were treated with the monoclonal antibody rituximab plus MTX. ... Additionally this will reduce treatment costs by avoiding the use of ineffective

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    In its late-stage pipeline Eisai has enviable prospects in oncology in the form of two very strong, innovative drugs. ... The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....